PROPANC BIOPHARMA, INC. Ttl Fee Amt
PROPANC BIOPHARMA, INC. (PPCB) had Ttl Fee Amt of $562.76 as of 2026-07-17, per its S-1 filed 2026-07-17.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-07-17
- 2026-07-17: Ttl Fee Amt $562.76.
- 2026-04-10: Ttl Fee Amt $231.39.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-07-17 | $562.76 S-1 · filed 2026-07-17 |
| 2026-04-10 | $231.39 S-1 · filed 2026-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |